InfuSystem (INFU) vs. The Competition Head to Head Analysis

InfuSystem (NYSE:INFU) is one of 233 public companies in the “Healthcare Providers & Services” industry, but how does it compare to its competitors? We will compare InfuSystem to similar companies based on the strength of its earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and valuation.

Institutional & Insider Ownership

71.1% of InfuSystem shares are held by institutional investors. Comparatively, 56.7% of shares of all “Healthcare Providers & Services” companies are held by institutional investors. 10.8% of InfuSystem shares are held by company insiders. Comparatively, 15.0% of shares of all “Healthcare Providers & Services” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for InfuSystem and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0	0	2	0	3.00
InfuSystem Competitors	1871	7744	13372	828	2.55

InfuSystem currently has a consensus price target of $17.50, suggesting a potential upside of 17.81%. As a group, “Healthcare Providers & Services” companies have a potential upside of 13.25%. Given InfuSystem’s stronger consensus rating and higher probable upside, research analysts clearly believe InfuSystem is more favorable than its competitors.

Valuation and Earnings

This table compares InfuSystem and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
InfuSystem	$144.44 million	$870,000.00	33.01
InfuSystem Competitors	$19.21 billion	$301.67 million	7.03

InfuSystem’s competitors have higher revenue and earnings than InfuSystem. InfuSystem is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

InfuSystem has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, InfuSystem’s competitors have a beta of 0.98, indicating that their average stock price is 2% less volatile than the S&P 500.

Profitability

This table compares InfuSystem and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
InfuSystem Competitors	-8.06%	-136.93%	-1.64%

Summary

InfuSystem beats its competitors on 9 of the 13 factors compared.

InfuSystem Company Profile

InfuSystem Holdings, Inc. provides infusion pumps, related medical equipment and support services to healthcare providers and patients. Its products are used in settings such as hospitals, clinics and patients’ homes, including for oncology and pain-management therapies. The company operates through its Integrated Therapy Services and Durable Medical Equipment Services businesses. Its offerings include infusion pump rentals and sales, equipment management, biomedical services, clinical support and related supplies.